Search results for "BONE"

showing 10 items of 2629 documents

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

2020

Autologous T cells engineered to express a chimeric antigen receptor (CAR) against the CD19 antigen are in the frontline of contemporary hemato-oncology therapies, leading to high remission rates in B-cell malignancies. Although effective, major obstacles involve the complex and costly individualized manufacturing process, and CD19 target antigen loss or modulation leading to resistant and relapse following CAR therapy. A potential solution for these limitations is the use of donor-derived γδT cells as a CAR backbone. γδT cells lack allogenecity and are safely used in haploidentical transplants. Moreover, γδT cells are known to mediate natural anti-tumor responses. Here, we describe a 14-da…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentImmunologyCell Culture TechniquesPriming (immunology)Mice SCIDImmunotherapy AdoptiveCD1903 medical and health sciencesMice0302 clinical medicineAntigenMice Inbred NODTransduction GeneticmedicineAnimalsHumansImmunology and Allergyimmuno oncologyB cell malignanciesOriginal ResearchLeukemiaReceptors Chimeric Antigenbiologychimeric antigen receptorChemistrygamma-delta T cellsReceptors Antigen T-Cell gamma-deltamedicine.diseaseXenograft Model Antitumor AssaysChimeric antigen receptorLeukemia030104 developmental biologyCytokinemedicine.anatomical_structureCell cultureCancer researchbiology.proteinBone marrowlcsh:RC581-607Genetic Engineering030215 immunologyFrontiers in Immunology
researchProduct

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology

2020

Bone remodeling is uncoupled in the multiple myeloma (MM) bone marrow niche, resulting in enhanced osteoclastogenesis responsible of MM-related bone disease (MMBD). Several studies have disclosed the mechanisms underlying increased osteoclast formation and activity triggered by the various cellular components of the MM bone marrow microenvironment, leading to the identification of novel targets for therapeutic intervention. In this regard, recent attention has been given to non-coding RNA (ncRNA) molecules, that finely tune gene expression programs involved in bone homeostasis both in physiological and pathological settings. In this review, we will analyze major signaling pathways involved …

0301 basic medicinelcsh:QH426-470Bone diseasenon-coding RNAReviewBiologyBiochemistryBone remodeling03 medical and health sciences0302 clinical medicineOsteoclastmicroRNAGeneticsmedicinetumor microenvironmentMolecular BiologyMultiple myelomamiRNAlong non-coding RNAmedicine.diseaseNon-coding RNALong non-coding RNAmultiple myelomalcsh:Genetics030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchbone diseaseBone marrowNon-Coding RNA
researchProduct

Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand.

2018

Wnt signaling is important for proper embryonic development, shaping cell fate and migration, stem cell renewal, and organ and tissue formation. Here, Luther et al. investigated the role of Wnt1 in osteoporosis. Patients with early-onset osteoporosis and with WNT1 mutations had low bone turnover and high fracture rates, and loss of Wnt1 activity caused fracture and osteoporosis in mice. Inducing Wnt1 in bone-forming cells increased bone mass in aged mice, and this process did not require Lrp5, a co-receptor involved in Wnt signaling. This study identifies Wnt1 as an anabolic (bone building) factor and suggests that it might be a therapeutic target for osteoporosis.WNT1 mutations in humans a…

0301 basic medicinemedicine.medical_specialtyAginganimal structuresAnabolismCellular differentiationOsteoporosis030209 endocrinology & metabolismMice TransgenicWnt1 ProteinLigandsBone and BonesBone remodeling03 medical and health sciencesFractures Bone0302 clinical medicineAnabolic AgentsOsteogenesisInternal medicineCortical BoneMedicineAnimalsHumansTransgenesOsteoblastsbusiness.industryIncidenceWnt signaling pathwayLRP5OsteoblastCell DifferentiationGeneral MedicineOrgan Sizemedicine.disease030104 developmental biologyEndocrinologymedicine.anatomical_structureLow Density Lipoprotein Receptor-Related Protein-5Osteogenesis imperfectaembryonic structuresMutationBone RemodelingbusinessScience translational medicine
researchProduct

Macrophage protease-activated receptor 2 regulates fetal liver erythropoiesis in mice.

2020

AbstractDeficiencies in many coagulation factors and protease-activated receptors (PARs) affect embryonic development. We describe a defect in definitive erythropoiesis in PAR2-deficient mice. Embryonic PAR2 deficiency increases embryonic death associated with variably severe anemia in comparison with PAR2-expressing embryos. PAR2-deficient fetal livers display reduced macrophage densities, erythroblastic island areas, and messenger RNA expression levels of markers for erythropoiesis and macrophages. Coagulation factor synthesis in the liver coincides with expanding fetal liver hematopoiesis during midgestation, and embryonic factor VII (FVII) deficiency impairs liver macrophage development…

0301 basic medicinemedicine.medical_specialtyBiologyThrombosis and Hemostasis03 medical and health sciencesMice0302 clinical medicineHepcidinInternal medicinemedicineMacrophageAnimalsReceptor PAR-2ErythropoiesisProtease-activated receptor 2Mice KnockoutFetusMacrophagesHematologymedicine.diseaseHemolysisHaematopoiesis030104 developmental biologyEndocrinologymedicine.anatomical_structureLiver030220 oncology & carcinogenesisbiology.proteinErythropoiesisBone marrowBlood advances
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct

Factors influencing serum 25-hydroxivitamin D levels and other bone metabolism parameters in healthy older women

2016

Objective: Older women have frequently low serum 25-hydroxivitamin D (25[OH]D) concentrations, high parathormone (PTH) levels and low bone mineral density (BMD) values. Endogenous synthesis, dietary habits, sunlight exposure and fat-mass-mediated storage may influence 25(OH)D levels and bone metabolism, but the relevance of these factors in the elderly has yet to be fully elucidated. We aimed to investigate the influence of dietary vitamin D intake and fat mass on serum 25(OH)D levels and bone metabolism in older women. Design: Cross-sectional. Setting: Community. Participants: 218 fit older women attending a biweekly mild fitness program. Measurements: Dietary habits was investigated throu…

0301 basic medicinemedicine.medical_specialtyBone densityMedicine (miscellaneous)030209 endocrinology & metabolism25-hydroxyvitamin D; bone metabolism; dietary vitamin D intake; elderly; fat mass; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and Gerontologydietary vitamin D intakeelderlyNOBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineVitamin D and neurologyFemoral neckBone mineralHyperparathyroidism030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryfat massmedicine.disease25-hydroxyvitamin Dmedicine.anatomical_structureEndocrinologychemistry25-hydroxyvitamin D dietary vitamin D intake fat mass bone metabolism elderlyCalcifediolSecondary hyperparathyroidismbone metabolismGeriatrics and GerontologybusinessThe journal of nutrition, health & aging
researchProduct

2021

Orthodontic treatment to correct dental malocclusions leads to the formation of pressure zones in the periodontal ligament resulting in a sterile inflammatory reaction, which is mediated by periodontal ligament fibroblasts (PDLF). Leptin levels are elevated in obesity and chronic inflammatory responses. In view of the increasing number of orthodontic patients with these conditions, insights into effects on orthodontic treatment are of distinct clinical relevance. A possible influence of leptin on the expression profile of PDLF during simulated orthodontic mechanical strain, however, has not yet been investigated. In this study, PDLF were exposed to mechanical strain with or without differen…

0301 basic medicinemedicine.medical_specialtyCatalysisBone resorptionProinflammatory cytokineInorganic Chemistry03 medical and health sciences0302 clinical medicineOsteoprotegerinInternal medicinemedicinePeriodontal fiberPhysical and Theoretical ChemistryReceptorMolecular BiologySpectroscopybiologyActivator (genetics)business.industryLeptinOrganic Chemistry030206 dentistryGeneral MedicineComputer Science Applications030104 developmental biologyEndocrinologyRANKLbiology.proteinbusinessInternational Journal of Molecular Sciences
researchProduct

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region

2019

Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low …

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismOsteoporosis030209 endocrinology & metabolismBone resorption makerAsia pacific regionCollagen Type IBone remodeling03 medical and health sciences0302 clinical medicineN-terminal telopeptideBone DensityOsteoporosis treatmentHealth caremedicineHumansRadiology Nuclear Medicine and imagingOrthopedics and Sports MedicineIntensive care medicineReimbursementAnabolicsBone mineralddc:616Hip Fracturesbusiness.industryAnti-resorptivesmedicine.diseasePeptide FragmentsBone formation makerOsteoporosisBone Remodeling030101 anatomy & morphologybusinessBiomarkersProcollagen
researchProduct

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

2019

Summary Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach. Methods Clinical perspective and updated literature search. Results The following areas are reviewed: …

0301 basic medicinemedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismeducationOsteoporosisPsychological interventioninhibitors of bone resorption030209 endocrinology & metabolismRisk AssessmentAnabolic agents03 medical and health sciencesTherapeutic approach0302 clinical medicineBone DensityRisk FactorsTreatment of osteoporosisInternal medicinemedicinefracture risk assessmentHumansanabolic agentsIntensive care medicineOsteoporosis PostmenopausalAgedAnabolic agents Fracture risk assessment FRAX Inhibitors of bone resorption Treatment of osteoporosisddc:616Postmenopausal womenbusiness.industryCorrectionFracture risk assessmentInhibitors of bone resorptionMiddle Agedtreatment of osteoporosismedicine.diseaseRheumatologyIncreased riskFemalePosition Paper030101 anatomy & morphologybusinessVery high riskAlgorithmsOsteoporotic FracturesFRAXOsteoporosis International
researchProduct